keyword
MENU ▼
Read by QxMD icon Read
search

sirolimus

keyword
https://www.readbyqxmd.com/read/29678162/tacrolimus-induced-parkinsonism-in-a-patient-after-liver-transplantation-case-report
#1
Karin Gmitterová, Michal Minár, Miroslav Žigrai, Zuzana Košutzká, Alice Kušnírová, Peter Valkovič
BACKGROUND: Hepatic encephalopathy may manifest by a wide spectrum of neuropsychiatric symptoms, including cognitive impairment, seizures or extrapyramidal symptoms. The liver transplant can lead to improvement of the signs of encephalopathy but subsequent immunosuppressive treatment might possess pronounced neurotoxicity. CASE PRESENTATION: We present a case report of a patient with chronic liver disease who developed signs of Parkinsonism after an orthotopic liver transplant, with consecutive immunosuppressant treatment with tacrolimus...
April 20, 2018: BMC Neurology
https://www.readbyqxmd.com/read/29675687/clinical-characteristics-in-lymphangioleiomyomatosis-related-pulmonary-hypertension-an-observation-on-50-patients
#2
Xiuxiu Wu, Wenshuai Xu, Jun Wang, Xinlun Tian, Zhuang Tian, Kaifeng Xu
Lymphangioleiomyomatosis (LAM) is a rare diffuse cystic lung disease. Knowledge on LAM-related pulmonary hypertension (PH) is limited. This study aimed to analyze the clinical characteristics of LAM with elevated pulmonary artery pressure (PAP) and evaluate the potential efficacy of sirolimus. The study involved 50 LAM patients who underwent echocardiography. According to the tricuspid regurgitation velocity (TRV), these patients were divided into the TRV ≤ 2.8 m/s group and TRV > 2.8 m/s group. Both groups comprised 25 females with an average age of 38...
April 19, 2018: Frontiers of Medicine
https://www.readbyqxmd.com/read/29668543/multiple-epstein-barr-virus-associated-smooth-muscle-sarcomas-of-the-gut-in-a-child-treated-for-acute-lymphoblastic-leukemia
#3
Cécile Boulanger, Maëlle de Ville de Goyet, Catherine de Magnée, Sophie Dupont, Christine Galant, An Van Damme, Bénédicte Brichard
A 7-year-old boy with a history of low-risk acute lymphoblastic leukemia developed multiple intussusceptions shortly after the end of maintenance therapy. Explorative laparotomy showed >10 polyps in the small intestine. Histologic examination revealed intestinal smooth muscle sarcomas associated with Epstein-Barr virus. The patient recovered well after partial cuneiform resection of the largest polyps and treatment with sirolimus. This case report indicates that these tumors may arise even after moderate transient immunosuppression and that association with acute lymphoblastic leukemia is possible although rarely described...
April 17, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29668485/prolonged-activity-and-toxicity-of-sirolimus-in-a-patient-with-metastatic-renal-perivascular-epithelioid-cell-tumor-a-case-report-and-literature-review
#4
Alessandra Raimondi, Francesca Colombo, Giulia Pintarelli, Carlo Morosi, Salvatore L Renne, Anna M Frezza, Maristella Saponara, Angelo P Dei Tos, Arabella Mazzocchi, Salvatore Provenzano, Paolo G Casali, Silvia Stacchiotti
Perivascular epithelioid cell tumor (PEComa) is a family of mesenchymal tumors. Conventional chemotherapy has little activity in this disease, but case reports are available on the activity of mammalian target of rapamycin inhibitors (e.g. sirolimus and temsirolimus). Pharmacokinetic assays of sirolimus are available as this drug has a precise therapeutic window and blood levels might be influenced by CYP3A4 polymorphisms and drug interactions. We report on a case of a patient with metastatic, progressive PEComa who started sirolimus at a dose of 5 mg/day with evidence of grade (G) 3 mucositis, G2 thrombocytopenia, and G1 leucopenia 10 days after the treatment started, in absence of concomitant medications or prohibited food assumption...
April 17, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29661597/clinical-performance-of-a-dedicated-self-apposing-stent-for-the-treatment-of-left-main-stem-disease-results-of-the-left-main-angioplasty-with-a-self-apposing-stent-the-matisse-study
#5
Bernardo Cortese, Antonio Montefusco, Fabrizio D'Ascenzo, Alessio La Manna, Giuseppe Andò, Teodoro Bisceglia, Gioel G Secco, Markus Meyer-Gessner, Wanha Wojciech, Paolo Sganzerla, Massimo Napodano, Gaetano Di Palma, Roberto A Latini, Corrado Tamburino, Pedro Silva Orrego, Andreas Baumbach
BACKGROUND: In the recent years percutaneous treatment of the left main stem (LM) has gained a precise role as a result of consistent scientific evidence vs. coronary artery bypass. A self-apposing stent offers an improved adaptation to the vessel wall, especially in case of tapered vessels; aim of this study was to investigate the role of a novel self-apposing, sirolimus-eluting stent (Stentys, France) for the treatment of LM coronary artery disease. METHODS AND RESULTS: MATISSE is a retrospective, multicenter registry, which enrolled 151 patients treated with the device at 17 international centers...
April 4, 2018: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/29661453/late-onset-post-transplantation-central-nervous-system-lymphoproliferative-disorder-case-report
#6
J Rego Silva, R A Macau, H Oliveira Coelho, F Camelo, P Cruz, A Mateus, A Oliveira, C Oliveira, A Ramos
Post-transplantation lymphoproliferative disorder (PTLD) is a heterogeneous group of conditions that complicate organ transplantation and are due to immunosuppression. Central nervous system (CNS)-PTLD is rare but its incidence is increasing. It often occurs late and is associated with kidney transplantation and Epstein-Barr virus (EBV) infection. Outcomes are poor. We present the case of a 77-year-old white male who received a cadaveric kidney transplant in 2003. Maintenance immunosuppression consisted of mycofenolate mofetil (MMF), cyclosporine, and prednisolone...
April 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29661440/renopancreatic-transplantation-evaluation-of-15-years-in-131-patients
#7
C G Marmanillo, C Langaro, J E Nicoluzzi, R T Belila, M Macri, R Zamprogna, M Luvizotto, M Takahashi
BACKGROUND: The most common multiple-organ transplant is the simultaneous pancreas-kidney transplantation (SPK). It is usually offered to patients who have insulin-dependent diabetes mellitus and those with diabetic nephropathy and renal failure that has already been established. In this study we present the results of 15 years of SPK in a transplant hospital center in Paraná, Brazil, and evaluated survival, immunosuppression, and transplant-related problems. METHODS: This study was a retrospective analysis of 131 SPK transplants performed at the Angelina Caron Hospital between January 2001 and December 2015...
April 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29656112/influence-of-immunosuppressive-drugs-on-the-cd30-molecule-in-kidney-transplanted-patients
#8
Patricia Cristina Grenzi, Érika Fernandes Campos, Hélio Tedesco-Silva, Claudia Rosso Felipe, Maria Fernanda Soares, José Medina-Pestana, Hinrich Peter Hansen, Maria Gerbase-DeLima
BACKGROUND: Soluble CD30 (sCD30) is a suggested marker for kidney transplantation outcomes. We investigated whether sCD30 serum levels are influenced by immunosuppression and whether they correlate with findings in protocol biopsies and with CD30 gene expression in peripheral blood mononuclear cells (PBMC). METHODS: We studied 118 kidney transplant recipients that initially received tacrolimus (TAC) and, at month-3, were converted or not to sirolimus (SRL). RESULTS: sCD30 serum levels gradually declined after transplantation, being the decline more pronounced in the SRL group...
April 12, 2018: Human Immunology
https://www.readbyqxmd.com/read/29651802/three-months-optical-coherence-tomography-analysis-of-a-biodegradable-polymer-sirolimus-eluting-stent
#9
Еvgeny Kretov, Ivan Naryshkin, Vitaly Baystrukov, Igor Grazhdankin, Aleksei Prokhorikhin, Dmitry Zubarev, Alexey Biryukov, Vladimir Verin, Andrey Boykov, Dastan Malaev, Evgeny Pokushalov, Alexander Romanov, Martin W Bergmann
OBJECTIVE: We aimed to assess early neointimal healing by optical coherence tomography (OCT) 3 months after implantation of the ultrathin Orsiro® sirolimus-eluting stent with biodegradable polymer. BACKGROUND: New generations of drug-eluting stents with biodegradable polymer have been developed to avoid the continued vascular irritation of durable polymers. METHODS: In this prospective, open-label study, 34 patients received an Orsiro® sirolimus-eluting stent with biodegradable polymer...
April 12, 2018: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/29622449/one-year-clinical-outcome-of-biodegradable-polymer-sirolimus-eluting-stent-in-all-comers-population-insight-from-the-ulisse-registry-ultimaster-italian-multicenter-all-comers-stent-registry
#10
Cosmo Godino, Alessandro Beneduce, Giuseppe Ferrante, Alfonso Ielasi, Andrea Carlo Pivato, Mauro Chiarito, Alberto Cappelletti, Giulia Perfetti, Valeria Magni, Eugenio Prati, Stefania Falcone, Adele Pierri, Stefano De Martini, Matteo Montorfano, Rosario Parisi, David Rutigliano, Nicola Locuratolo, Angelo Anzuini, Maurizio Tespilli, Alberto Margonato, Alberto Benassi, Carlo Briguori, Franco Fabbiocchi, Bernhard Reimers, Antonio Bartorelli, Antonio Colombo
BACKGROUND: This study was designed to confirm in a large population of unselected patients the promising results of Ultimaster® biodegradable polymer sirolimus-eluting stent (BP-SES) already shown in previous trial. METHODS: ULISSE is an observational, multicenter, national registry evaluating all patients undergoing PCI with the Ultimaster® BP-SES. Incidence of 1-year TLF (cardiac death or target vessel MI or clinically indicated TLR) was the primary endpoint...
June 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29619983/acute-thrombogenicity-of-fluoropolymer-coated-versus-biodegradable-and-polymer-free-stents
#11
Sho Torii, Qi Cheng, Hiroyoshi Mori, Michael J Lipinski, Eduardo Acampado, Laura E L Perkins, Syed F Hossainy, Stephen D Pacetti, Frank D Kolodgie, Renu Virmani, Aloke V Finn
AIMS: Durable-fluoropolymer coated everolimus-eluting stents (FP-EES) have shown lower rates of stent thrombosis (ST) versus bare-metal stents (BMS) and 1st-generation bioabsorbable-polymer (BP) DES. However, the specific role of the FP in thromboresistance has not been explored. METHODS AND RESULTS: A total of 57 stents were assessed in 3 separate ex-vivo swine arterio-venous shunt-model experiments [1st-shunt-experiment, custom-made fluoropolymer-coated BMS (FP-only) vs...
April 3, 2018: EuroIntervention
https://www.readbyqxmd.com/read/29619395/sirolimus-in-refractory-cronkhite-canada-syndrome-and-focus-on-standard-treatment
#12
Catherine Langevin, Hugo Chapdelaine, Jean-Maxime Picard, Pierre Poitras, Raymond Leduc
Cronkhite-Canada syndrome is a rare syndrome consisting of extensive gastrointestinal polyposis and ectodermal changes including cutaneous hyperpigmentation, alopecia, and onychodystrophy. We report the case of a 45-year-old Caucasian male patient who failed multiple treatments over 2 years including steroids, azathioprine, adalimumab, and cyclosporine. He had recurrent and prolonged hospitalizations because of diarrhea, abdominal pain, weight loss, and malnutrition. Sirolimus was initiated with a significant clinical and endoscopic benefit apparent within, respectively, 2 and 8 weeks...
January 2018: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/29611172/prevention-of-in-stent-restenosis-with-endothelial-progenitor-cell-epc-capture-stent-placement-combined-with-regional-epc-transplantation-an-atherosclerotic-rabbit-model
#13
You-Hua Huang, Qiang Xu, Tao Shen, Jian-Ke Li, Jing-Yu Sheng, Hong-Jian Shi
BACKGROUND: Even with drug-eluting stents, the risk of in-stent restenosis (ISR) remains high. The goal of this study was to investigate the use of an endothelial progenitor cell (EPC) capture stent plus regional EPC transplantation to reduce the ISR rate. METHODS: Endothelial progenitor cell capture stents were fabricated using fibrin gel and anti-CD34 plus anti-VEGFR-2 dual antibodies. Twenty male New Zealand white rabbits established as an atherosclerotic model were randomly divided into two groups: group 1 (n = 10), in which EPC capture stents were deployed into the right iliac artery; and group 2 (n = 10), in which sirolimus-eluting stents were placed...
April 3, 2018: Cardiology Journal
https://www.readbyqxmd.com/read/29610165/a-case-report-of-2-sirolimus-related-deaths-among-infants-with-kaposiform-hemangioendotheliomas
#14
Hanru Ying, Congzhen Qiao, Xi Yang, Xiaoxi Lin
Kaposiform hemangioendothelioma (KHE) is a rare infiltrative vascular tumor that is potentially life-threatening when presenting with Kasabach-Merritt phenomenon (KMP). KMP is clinically characterized as severe thrombocytopenia and hypofibrinogenemia and therefore is associated with a high mortality rate. There is no standard of cure for KHE currently. Potential medications, including corticosteroids, propranolol, and chemotherapy drugs such as sirolimus, are often used for alleviating KHE symptoms. Although some case reports of sirolimus treatment have shown promising results with recovered coagulant parameters, the off-target effects may cause severe problems...
April 2018: Pediatrics
https://www.readbyqxmd.com/read/29610164/-pneumocystis-jirovecii-pneumonia-during-sirolimus-therapy-for-kaposiform-hemangioendothelioma
#15
Thomas B Russell, Emily K Rinker, Claire S Dillingham, Laurence B Givner, Thomas W McLean
Sirolimus is an effective therapy for children with kaposiform hemangioendothelioma with or without the Kasabach-Merritt phenomenon. We report the case of a child with kaposiform hemangioendothelioma and the Kasabach-Merritt phenomenon who developed Pneumocystis carinii pneumonia (PCP) while on sirolimus and a prednisolone taper, after lack of adequate response to prednisolone, propranolol, and vincristine. He had a prompt positive clinical and laboratory response to sirolimus, but 4 weeks after starting it, at the age of 4 months, he developed PCP...
April 2018: Pediatrics
https://www.readbyqxmd.com/read/29610003/-therapeutic-strategy-for-the-treatment-of-non-infectious-uveitis-proposed-by-an-expert-panel
#16
E Diwo, P Sève, S Trad, P Bielefeld, D Sène, S Abad, A Brézin, P Quartier, I Koné Paut, M Weber, C Chiquet, M H Errera, J Sellam, P Cacoub, G Kaplanski, L Kodjikian, B Bodaghi, D Saadoun
Conventional immunosuppressive drugs, anti-TNF alpha and other biotherapies used in clinical practice are capable of controlling non-infectious anterior uveitis, posterior uveitis and panuveitis. The present work has been led by a multidisciplinary panel of experts, internists, rheumatologists and ophthalmologists and is based on a review of the literature. In case of corticodependency or sight-threatening disease, conventional immunosuppressive drugs (methotrexate, azathioprine and mycophenolate mofetil) and/or anti-TNF alpha (adalimumab, infliximab) are used to achieve and maintain remission...
March 30, 2018: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/29607465/sirolimus-enhances-remission-induction-in-patients-with-high-risk-acute-myeloid-leukemia-and-mtorc1-target-inhibition
#17
Margaret T Kasner, Rosemarie Mick, Grace R Jeschke, Matthew Carabasi, Joanne Filicko-O'Hara, Neal Flomenberg, Noelle V Frey, Elizabeth O Hexner, Selina M Luger, Alison W Loren, James K Mangan, John L Wagner, Mark Weiss, Martin Carroll, Alexander E Perl
Background Mammalian Target of Rapamycin Complex 1 (mTORC1) inhibitors enhance chemotherapy response in acute myelogenous leukemia (AML) cells in vitro. However whether inhibiting mTORC1 enhances clinical response to AML chemotherapy remains controversial. We previously optimized measurement of mTORC1's kinase activity in AML blasts during clinical trials using serial phospho-specific flow cytometry of formaldehyde-fixed whole blood or marrow specimens. To validate mTORC1 as a therapeutic target in AML, we performed two clinical trials combining an mTORC1 inhibitor (sirolimus) and MEC (mitoxantrone, etoposide, cytarabine) in patients with relapsed, refractory, or untreated high-risk AML...
April 2, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29607135/ultrathin-strut-biodegradable-polymer-sirolimus-eluting-stents-being-wary-or-going-with-the-flow
#18
EDITORIAL
Salvatore Cassese, Anna Lena Lahmann, Michael Joner
No abstract text is available yet for this article.
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29607127/is-the-sirolimus-encapsulated-balloon-a-reliable-tool-for-treating-the-in-stent-restenosis-insights-from-the-sabre-trial
#19
EDITORIAL
Daniele Andreini, Daniela Trabattoni
No abstract text is available yet for this article.
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29607125/novel-treatments-for-in-stent-restenosis-sirolimus-eluting-balloons-enter-the-arena
#20
EDITORIAL
Raffaele Piccolo, Tullio Niglio, Anna Franzone, Bruno Trimarco, Giovanni Esposito
No abstract text is available yet for this article.
February 2018: Journal of Thoracic Disease
keyword
keyword
4707
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"